Dr. Peter Williamson is the Tanna Schulich Chair in Neurosciences and Mental Health and leads the Schizophrenia group at LHSC. He was the first in the world to assess glutamatergic metabolites in vivo and one of the first to characterize intrinsic network anomalies in schizophrenia, both heavily cited contributions. This has led to an influential hypothesis for glutamatergic transmission in schizophrenia and progress towards a final common pathway He has the longest track record (16 years) of studying patients at ≥4T of any physician in the world.

Dr. Ruth Lanius, the Harris-Woodman Chair in Psyche and Soma, leads the posttraumatic stress disorders group and is arguably the leading neuroimager in PTSD. Dr. Lanius has proposed a new subtype of the disorder in the lead article of the June, 2010 issue of the American Journal of Psychiatry and is the senior editor of The Impact of Early Life Trauma on Health and Disease: The Hidden Epidemic published by Cambridge University Press in 2010. She collaborates withDr. Paul Frewen, a new investigator who has recently joined the group and has developed innovative brain imaging paradigms for studying higher-order emotional processes including social emotions and sense of self in these.

Prof. Jean Théberge is a NARSAD Young Investigator and Assistant Professor of Medical Imaging and a Lawson Scientist. Best known for his seminal work measuring glutamatergic abnormalities in longitudinal studies of schizophrenia, his expertise in high and ultra-field applications of MRS and resting state fMRI to the study of neuropsychiatric disorders have made him an authority in this area. He has worked at ≥4T since 1998.

Dr. Elizabeth Osuch, the Rea Chair in Mood and Anxiety Disorders, and Prof. Derek Mitchell lead the mood and anxiety disorders group. Coming from NIMH, both have made numerous contributions to understanding the neuronal circuitry of mood with highly innovative fMRI paradigms. Dr. Osuch has developed the unique in London First Episode Mood and Anxiety Program (FEMAP) which is a clinical treatment and research program for youth which provides ready access to the investigation of these illnesses in the early stages, before years of treatment.